Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Recurrent urinary tract infections, Decreased circulating immunoglobulin concentration, Decreased total lymphocyte count, and Eczematoid dermatitis and 2 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 3 | Recurrent urinary tract infections, Recurrent respiratory infections, Decreased total neutrophil count |
MSN encodes moesin (577 aa). Ezrin-radixin-moesin (ERM) family protein that connects the actin cytoskeleton to the plasma membrane and thereby regulates the structure and function of specific domains of the cell cortex. Highest expression in Lung (365.9 TPM) and Cells EBV-transformed lymphocytes (361.1 TPM).
Combined immunodeficiency due to moesin deficiency is caused by mutations in the MSN gene on chromosome X.
The MSN protein participates in MSN(2-448)-ALK(1064-1620) fusion, MSN(2-448)-p-7Y-ALK(1064-1620) fusion, and Expression of Moesin pathways.
MSN is classified as a druggable target (Cell Surface and Clinically Actionable categories) with score 0.0.
Genetic testing for MSN is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for combined immunodeficiency due to moesin deficiency has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for combined immunodeficiency due to moesin deficiency.
5 publications have been identified in PubMed for combined immunodeficiency due to moesin deficiency. Research spans Case Report / Case Series (60%), Diagnostic / Biomarker (20%), and Basic Science / Preclinical (20%).
Liu Q (2025). [PMID: 40788322](https://pubmed.ncbi.nlm.nih.gov/40788322/). *J Clin Immunol*. [Case Report / Case Series]
Ichioka S (2024). [PMID: 38640733](https://pubmed.ncbi.nlm.nih.gov/38640733/). *Biochem Biophys Res Commun*. [Basic Science / Preclinical]
Niehues T (2024). [PMID: 39381601](https://pubmed.ncbi.nlm.nih.gov/39381601/). *Allergol Select*. [Diagnostic / Biomarker]
Sun B (2024). [PMID: 38922539](https://pubmed.ncbi.nlm.nih.gov/38922539/). *J Clin Immunol*. [Case Report / Case Series]
Castillo-Aleman YM (2024). [PMID: 39781543](https://pubmed.ncbi.nlm.nih.gov/39781543/). *Case Reports Immunol*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 1:49 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about combined immunodeficiency due to moesin deficiency
Kidneys and urinary system |
1 |
Recurrent urinary tract infections |
Skin | 1 | Eczematoid dermatitis |
Lungs and breathing | 1 | Recurrent respiratory infections |